Keywords: Dendreon, Provenge, Prostate cancer, Sales update

Dendreon upbeat on Provenge sales

Article | 08 January 2012

Print This

US biotech firm Dendreon (Nasdaq: DNDN) pleased investors last week when it reported that revenue of its breakthrough prostate cancer ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in